💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
User | Tweets |
---|---|
@newsfilterio | 5 |
@TradeWithAlerts | 4 |
@MarcJacksonLA | 3 |
@SwingTradeBot | 2 |
@EdgarInsider | 2 |
![]() |
@NupeSauce I SEE YOU $GRFS April 19th 2021, 10:04pm |
![]() |
@SAFTHELABEL RT @NupeSauce: ? it’s time for $Grfs to blow! April 19th 2021, 8:04pm |
![]() |
@lilnickysmith $GRFS spike April 19th 2021, 4:04pm |
![]() |
@NupeSauce ? it’s time for $Grfs to blow! April 19th 2021, 3:04am |
![]() |
@themechtutor @cdn_investing How about $GRFS. Grifols seems quite undervalued. April 17th 2021, 2:04pm |
![]() |
@newsfilterio Form 6-K (report of foreign issuer [rules 13a-16 and 15d-16]) filed with the SEC $GRFS https://t.co/Gy9RXlgDac April 17th 2021, 6:04am |
![]() |
@MarcJacksonLA $GRFS GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology https://t.co/VjmKutxAok April 16th 2021, 2:04pm |
![]() |
@EdgarInsider New Form 6-K entry filed by $GRFS #Grifols SA https://t.co/CuIHawRJDh April 16th 2021, 2:04pm |
![]() |
@newsfilterio Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030 $GRFS https://t.co/dGQzyWKWtz April 16th 2021, 6:04am |
![]() |
@newsfilterio GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology $GRFS https://t.co/fA4dn7QwIy April 15th 2021, 4:04pm |
![]() |
@otcdynamics $GRFS GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology https://t.co/liNyGL7faA April 15th 2021, 4:04pm |
![]() |
@FlashAlert_me $GRFS [15s. delayed]: Issued Press Release on April 15, 11:59:00: GigaGen Publishes Research on Company’s Recombina… https://t.co/QFozuY4dIj April 15th 2021, 4:04pm |
![]() |
@StckPro $GRFS NEW ARTICLE : Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030… https://t.co/ArIza08mzi April 15th 2021, 1:04pm |
![]() |
@SwingTradeBot 200 DMA Support today: $GRFS ... https://t.co/LjP7KUcNnp April 14th 2021, 2:04pm |
![]() |
@TradeWithAlerts Large Print $GRFS Size: 262186 Price: 17.83 Time: 934 Amount: $4,674,776.38 April 14th 2021, 1:04pm |
![]() |
@TradeWithAlerts Large Print $GRFS Size: 250000 Price: 17.45 Time: 1504 Amount: $4,362,500.00 April 12th 2021, 7:04pm |
![]() |
@IrishInvestor This #Biotech does #Plasma Collection for Diseases, Medications & Viruses ? Like Covid $GRFS #thinkorswim https://t.co/NhF2tNNDki April 12th 2021, 6:04pm |
![]() |
@SwingTradeBot 200 DMA Support today: $GRFS $VICR ... https://t.co/LjP7KUcNnp April 12th 2021, 2:04pm |
![]() |
@TradeWithAlerts Large Print $GRFS Size: 129050 Price: 17.75 Time: 1037 Amount: $2,290,637.50 April 12th 2021, 2:04pm |
![]() |
@newsfilterio Form 20-F (annual and transition report of foreign private issuers [sections 13 or 15(d)]) filed with the SEC $GRFS https://t.co/PvzzNa37Nh April 10th 2021, 6:04am |
![]() |
@MarcJacksonLA $GRFS Grifols Files Annual Report https://t.co/LfDAuo2V0f April 9th 2021, 3:04pm |
![]() |
@FlashAlert_me $GRFS [15s. delayed]: Issued Press Release on April 09, 10:30:00: Grifols 2020 Annual Report on Form 20-F filed wit… https://t.co/z6ufJIwdQe April 9th 2021, 2:04pm |
![]() |
@newsfilterio Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021 $GRFS https://t.co/IxFjhRBiPf April 9th 2021, 2:04pm |
![]() |
@stock_titan $GRFS Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021 https://t.co/zBimf7ppuQ April 9th 2021, 2:04pm |
![]() |
@StockTexts $GRFS Grifols, S.A. SEC Filing: Form 20-F https://t.co/XWz4hB68Nb April 9th 2021, 1:04pm |
![]() |
@fintel_io $GRFS / Grifols files form 20-F https://t.co/zWdO0GXNEG April 9th 2021, 1:04pm |
![]() |
@M_Feratovic RT @RoyalOakInc: There has been much talk of elites using the blood of youth... Hmmm. $GRFS was mentioned April 8th 2021, 1:04pm |
![]() |
@RoyalOakInc There has been much talk of elites using the blood of youth... Hmmm. $GRFS was mentioned https://t.co/Ise52keXZD April 8th 2021, 1:04pm |
![]() |
@MarcJacksonLA $GRFS Grifols Advances In Plan To Acquire 7 Plasma Centers In US ... https://t.co/69IJbIYiIU April 7th 2021, 2:04pm |
![]() |
@TradeWithAlerts Large Print $GRFS Size: 120319 Price: 17.05 Time: 902 Amount: $2,051,438.95 April 7th 2021, 1:04pm |
![]() |
@StockTexts $GRFS Grifols, S.A. SEC Filing: Form 6-K https://t.co/qOcKngGxgk April 7th 2021, 12:04pm |
![]() |
@fintel_io $GRFS / Grifols files form 6-K https://t.co/zWdO0GXNEG April 7th 2021, 12:04pm |
![]() |
@EdgarInsider Filing for 6-K has been made with the SEC: $GRFS #Grifols SA https://t.co/ze7iSPCksK April 7th 2021, 12:04pm |
![]() |
@Gambiste1 RT @OpenOutcrier: $GRFS (-0.5% pre) Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globu… April 6th 2021, 10:04am |
![]() |
@SwingTradeBot Rose Above 50 DMA today: $GRFS ... https://t.co/qwiJH6vr1O April 5th 2021, 4:04pm |
![]() |
@MarcJacksonLA $GRFS Grifols’ combination treatment fails to meet endpoints in Covid-19 study https://t.co/6ROFGcRKUk via @Clinical Trials Arena April 5th 2021, 3:04pm |
![]() |
@OpenOutcrier $GRFS (-0.5% pre) Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune… https://t.co/KAGHQC73BH April 5th 2021, 11:04am |
![]() |
@Briefingcom $GRFS: Grifols, S.A. reports topline data from NIAID Phase 3 ITAC trial did not meet primary endpoint https://t.co/IutuvUtseZ April 5th 2021, 11:04am |
![]() |
@MarcJacksonLA $GRFS Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins a… https://t.co/RISqIYG0w7 April 3rd 2021, 2:04pm |
![]() |
@NupeSauce $GRFS I dodged the dip. Keep dropping babyyyy April 3rd 2021, 12:04pm |
![]() |
@BertrandBio RT @BioStocks: $GRFS Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with #COVID… April 2nd 2021, 4:04pm |
![]() |
@BioStocks $GRFS Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients wi… https://t.co/AZaCYhSMBs April 2nd 2021, 4:04pm |
![]() |
@sbwcws Grifols Phase 3 study in hospitalized Covid patients did not meet endpoints $GRFS April 2nd 2021, 3:04pm |
![]() |
@SwingTradeBot Recent $GRFS technical alerts: Expansion Pivot Sell Setup plus 9 more alerts... https://t.co/F1c5WU78fW April 2nd 2021, 3:04pm |
![]() |
@FlashAlert_me $GRFS [15s. delayed]: Issued Press Release on April 02, 11:18:00: Grifols announces topline data from NIAID Phase 3… https://t.co/GUBfb3qkJh April 2nd 2021, 3:04pm |
![]() |
@Beeken_health $GRFS - Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins… https://t.co/tM8UFdTauS April 2nd 2021, 3:04pm |
![]() |
@StckPro $GRFS NEW ARTICLE : Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmu… https://t.co/TT98sHoMzJ April 2nd 2021, 3:04pm |
![]() |
@stock_titan $GIKLY $GRFS Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune glob… https://t.co/HgHVqu9F2n April 2nd 2021, 3:04pm |
![]() |
@NupeSauce $GRFS $20 by 2021? March 31st 2021, 4:03pm |
![]() |
@MarcJacksonLA $GRFS Grifols Upgraded to Outperform at Credit Suisse Group | https://t.co/NKb5pRLCDo https://t.co/Xzf9FVZn2Z March 29th 2021, 3:03pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.